Lupin gets final USFDA nod for Mylan's skin disease cream

Pharma major Lupin today said it has received final approval from the US health regulator to market its generic version of Mylan's triamcinolone acetonide cream used for treatment of skin disease.
The approval is for multiple strengths of 0.025 per cent, 0.1 per cent and 0.5 per cent triamcinolone acetonide cream which is used for relief from inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, the company said in a BSE filing.
"Lupin shall commence promoting the product shortly," it added.
Citing IMS MAT data up to September 2016, Lupin said triamcinolone acetonide cream had sales of USD 55.7 million in the US market.